a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL.

Drug Category: Array
Conference Category: Array
Lead Author: O'Brien, et al.
Published Date: 09/09/2015
Download Link: /wp-content/uploads/2019/03/1202%201303%20iwCLL%202015%20FINAL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top